PMID- 36613966
OWN - NLM
STAT- MEDLINE
DCOM- 20230111
LR  - 20230111
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 1
DP  - 2022 Dec 28
TI  - Effects of Chicken Serum Metabolite Treatment on the Blood Glucose Control and 
      Inflammatory Response in Streptozotocin-Induced Type 2 Diabetes Mellitus Rats.
LID - 10.3390/ijms24010523 [doi]
LID - 523
AB  - Chickens can live healthy without adverse effects despite high blood glucose 
      levels. However, the blood biomolecules responsible for maintaining chronic 
      hyperglycemia are unknown. Here, the effects of chicken serum metabolite 
      treatment on blood glucose control and inflammatory response in streptozotocin 
      (STZ)-induced Type 2 Diabetes Mellitus (T2DM) rats were investigated. First, 
      chicken serum treatment reduced the advanced glycation end-products (AGEs) and 
      blood glucose levels in STZ-induced T2DM rats. Second, insulin/glucose-induced 
      acute hypoglycemic/hyperglycemic chickens and the blood biomolecules were 
      screened via nontargeted ultra-performance liquid chromatography with mass 
      spectroscopy (UPLC-MS), identifying 366 key metabolites, including DL-arginine 
      and taurine, as potential markers for chronic hyperglycemia in chickens. Finally, 
      DL-arginine functions for blood glucose control and inflammatory response were 
      evaluated. We found that DL-arginine reduced the levels of blood glucose and AGEs 
      in STZ-induced T2DM rats. In addition, DL-arginine treatment upregulated the 
      glucose transporter type 4 (GLUT4) expression in the muscles and downregulated 
      the advanced glycation end products receptor-1 (AGER1) expression in the liver 
      and nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) 
      expression in the pancreas and thymus tissues. Overall, these results demonstrate 
      that serum metabolite of DL-arginine could maintain blood glucose homeostasis and 
      suppress the inflammatory response in chickens. Therefore, DL-arginine may be a 
      novel target for developing therapeutic agents to regulate hyperglycemia.
FAU - Hu, Xuan
AU  - Hu X
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Liu, Xueming
AU  - Liu X
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Guo, Yujiao
AU  - Guo Y
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Li, Yi
AU  - Li Y
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Cao, Zhengfeng
AU  - Cao Z
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Chen, Guohong
AU  - Chen G
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
FAU - Xu, Qi
AU  - Xu Q
AD  - Jiangsu Key Laboratory for Animal Genetic, Breeding and Molecular Design, 
      Yangzhou University, Yangzhou 225009, China.
LA  - eng
PT  - Journal Article
DEP - 20221228
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 94ZLA3W45F (Arginine)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Arginine
MH  - Blood Glucose/metabolism
MH  - Chickens/metabolism
MH  - Chromatography, Liquid
MH  - *Diabetes Mellitus, Experimental/metabolism
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Glycation End Products, Advanced
MH  - Glycemic Control
MH  - *Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents
MH  - Insulin/metabolism
MH  - Streptozocin
MH  - Tandem Mass Spectrometry
PMC - PMC9820086
OTO - NOTNLM
OT  - DL-arginine
OT  - blood glucose
OT  - chicken
OT  - inflammatory response
OT  - streptozotocin-induced rats
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/11 06:00
PMCR- 2022/12/28
CRDT- 2023/01/08 01:23
PHST- 2022/10/12 00:00 [received]
PHST- 2022/12/03 00:00 [revised]
PHST- 2022/12/22 00:00 [accepted]
PHST- 2023/01/08 01:23 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/12/28 00:00 [pmc-release]
AID - ijms24010523 [pii]
AID - ijms-24-00523 [pii]
AID - 10.3390/ijms24010523 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Dec 28;24(1):523. doi: 10.3390/ijms24010523.